Selank is a synthetic heptapeptide developed in Russia, and every documented route for it is non-oral, because the peptide does not survive digestion. The published Russian clinical record delivered it intranasally as a 0.15 percent solution in finite courses, while the gray-market pattern is reconstituted powder injected subcutaneously; neither rests on the large randomized trials that would make any figure a validated dose.
Every documented route of Selank administration is non-oral, with the Russian clinical literature reporting intranasal delivery of a 0.15 percent solution in roughly ten-to-fourteen-day courses, and none of these figures resting on validated therapeutic evidence.
The formal Russian trials and the gray-market community diverge on route. Nearly all of the published clinical work used intranasal delivery of a 0.15 percent solution, whereas self-administration outside that setting centers on subcutaneous injection of reconstituted powder. The split matters because the absorbed fraction differs sharply between the two, so the same microgram figure does not carry the same meaning across routes.
| Criteria | Intranasal (clinical) | Subcutaneous (gray-market) |
|---|---|---|
| Formulation | 0.15% aqueous solution | Reconstituted lyophilized powder |
| Setting | Russian clinical trials | Vendor pages, user forums |
| Absorbed fraction | Variable; lost to drip and swallowing | Nearly the full dose under the skin |
| Regulatory status | Not validated outside Russia | Sold as research chemical, not for human use |
Intranasal delivery of a 0.15 percent solution dominates the published Russian trials while subcutaneous injection characterizes gray-market use, and intramuscular administration is rarely if ever described in the primary literature.
Oral dosing fails for Selank because the digestive tract is built to take peptides apart. A molecule of this kind meets a sequence of barriers between the mouth and the bloodstream, and the published pharmacology places its oral bioavailability at effectively zero.
Gastric acid, pancreatic and brush-border proteases, poor epithelial permeability, and hepatic first-pass metabolism together render oral bioavailability of a peptide like Selank effectively negligible, which is why every documented route bypasses the gastrointestinal tract.
The Russian clinical papers describe Selank as a 0.15 percent aqueous solution, a concentration statement that fixes how many micrograms sit in each metered instillation. Across the anxiety and generalized-anxiety-disorder work the reported daily totals cluster in a range rather than at a single figure, and reporting conventions differ enough that two papers are not always directly comparable.
Across the Russian clinical literature Selank appears as a 0.15 percent aqueous solution given at daily totals ranging from several hundred to a few thousand micrograms in divided instillations over roughly ten-to-fourteen-day courses, reported in small early-phase trials rather than as a validated dosing standard.
The injectable figures that circulate come from vendor product pages and user forums, not trials, and they typically describe a few hundred micrograms per subcutaneous injection once or twice daily, often in cycles. These numbers carry a precision and safety problem the clinical figures do not, because a self-reconstituted dose is only as accurate as the concentration math and syringe reading behind it.
Gray-market self-administration figures of a few hundred micrograms per subcutaneous injection once or twice daily are anecdotal reports from vendor pages and forums, not clinically validated doses, and they carry dose-calculation and sterility risks that no controlled setting would tolerate.
Selank ships as a lyophilized, freeze-dried powder that has to be dissolved before delivery, and the handling described in the research literature follows a consistent sequence. The diluent is usually bacteriostatic water for an injectable preparation or sterile water or saline for a nasal one, with the bacteriostatic option favored when the solution will be held over several days.
Reconstitution described in the research literature dissolves the lyophilized powder in bacteriostatic water for injection or sterile water for nasal use, sets the working concentration as vial mass divided by diluent volume, and relies on gentle swirling rather than shaking to protect the fragile peptide.
Storage for Selank splits cleanly into two states, and the difference is stark. As a sealed lyophilized powder the material is comparatively robust, while a reconstituted solution begins degrading from the moment water is added.
Sealed lyophilized Selank stays stable frozen or refrigerated while dry, whereas a reconstituted solution held at two to eight degrees Celsius is generally treated as usable for only a few weeks and is discarded once cloudiness, particulates, or discoloration appear.
A defining feature of the Russian protocols is that they dosed in finite courses rather than open-endedly, commonly on the order of ten to fourteen days and sometimes repeated after a break. That structure reflects study design more than pharmacology, because a bounded window lets investigators administer the peptide and then measure an anxiolytic or nootropic response.
| Dimension | Course-based study protocol | Chronic pharmaceutical regimen |
|---|---|---|
| Duration | ~10 to 14 days, sometimes repeated | Daily for months or years |
| Purpose | Defined window to measure a response | Ongoing control of a condition |
| Breaks | Washout or rest intervals between courses | Continuous, no scheduled washout |
| Shape | Bounded intervention plus observation | Standing maintenance schedule |
The Russian Selank protocols dosed in finite courses of roughly ten to fourteen days built around measuring a response, a study-design parameter that differs fundamentally from a chronic daily regimen and is not a personal dosing calendar.
Every dose number attached to Selank is documentation, not instruction, and the reasons stack across law, science, and supply. Selank is not an approved medicine in the United States, the European Union, or most jurisdictions, the human evidence is a body of small early-phase Russian trials rather than large randomized controlled studies, and gray-market vials carry no pharmacopeial quality control.
Selank is not an approved medicine in the United States, the European Union, or most jurisdictions, its human evidence rests on small early-phase Russian trials rather than large randomized controlled studies, and gray-market vials lack pharmacopeial quality control, so every reported figure is documentation rather than validated therapeutic guidance.
Educational use only. This article describes what the published scientific and clinical literature reports about Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
